NetworkNewsBreaks – TapImmune, Inc. (NASDAQ: TPIV) HER2-Targeted Vaccine to be Evaluated in Phase 2 Study Funded by US Department of Defense
Clinical-stage immuno-oncology company TapImmune, Inc. (NASDAQ: TPIV) this morning announced that its collaborators at the Mayo Clinic recently received a $3.7 million grant from the U.S. Department of Defense (DoD) to conduct a Phase 2 clinical study on the company’s HER2/neu-targeted T-cell vaccine. The DoD-funded study will evaluate women diagnosed with an early form of breast cancer called ductal carcinoma in situ (DCIS), and, if successful, could clear the way for TapImmune’s vaccine to replace standard surgery and chemotherapy by becoming part of a routine immunization schedule for preventing breast cancer in healthy women. “This is our second T-cell vaccine…